Marshall Wace
XENE icon

Marshall Wace’s Xenon Pharmaceuticals XENE Stock Holding History

Marshall Wace’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.6M Buy
+689,342
New +$38.3M 0.03% 439
2026
Q1 		– Sell
-162,551
Closed -$7.29M – 3733
2025
Q4 		$7.29M Sell
162,551
-449,431
-73% -$18.9M 0.01% 994
2025
Q3 		$24.6M Sell
611,982
-408,272
-40% -$14.4M 0.02% 567
2025
Q2 		$31.9M Buy
1,020,254
+262,109
+35% +$8.55M 0.04% 422
2025
Q1 		$25.4M Sell
758,145
-141,573
-16% -$5.38M 0.03% 451
2024
Q4 		$35.3M Sell
899,718
-295,762
-25% -$12.2M 0.04% 370
2024
Q3 		$47.1M Sell
1,195,480
-189,194
-14% -$7.63M 0.06% 295
2024
Q2 		$54M Sell
1,384,674
-65,668
-5% -$2.62M 0.07% 247
2024
Q1 		$62.4M Sell
1,450,342
-78,306
-5% -$3.6M 0.1% 207
2023
Q4 		$70.4M Sell
1,528,648
-625,746
-29% -$22.1M 0.12% 171
2023
Q3 		$73.6M Sell
2,154,394
-166,025
-7% -$6.21M 0.15% 132
2023
Q2 		$89.3M Sell
2,320,419
-167
-0% -$6.64K 0.17% 123
2023
Q1 		$83.1M Sell
2,320,586
-45,592
-2% -$1.68M 0.18% 125
2022
Q4 		$93.3M Sell
2,366,178
-444,917
-16% -$16.2M 0.21% 97
2022
Q3 		$101M Buy
2,811,095
+820,723
+41% +$29.5M 0.22% 86
2022
Q2 		$60.5M Buy
1,990,372
+456,314
+30% +$13.8M 0.12% 167
2022
Q1 		$46.9M Buy
1,534,058
+313,101
+26% +$9.37M 0.09% 244
2021
Q4 		$38.1M Buy
1,220,957
+1,191,154
+3,997% +$35.6M 0.07% 283
2021
Q3 		$456K Buy
29,803
+19,350
+185% +$336K ﹤0.01% 2432
2021
Q2 		$195K Buy
+10,453
New +$193K ﹤0.01% 2450
2020
Q4 		– Sell
-37,345
Closed -$413K – 2226
2020
Q3 		$413K Sell
37,345
-45,567
-55% -$536K ﹤0.01% 1285
2020
Q2 		$1.04M Buy
+82,912
New +$1.06M 0.01% 982
2020
Q1 		– Sell
-48,606
Closed -$637K – 2105
2019
Q4 		$637K Buy
+48,606
New +$511K ﹤0.01% 1096

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Marshall Wace's XENE Position: Q2 2026 in Review

Marshall Wace opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 689,342 shares worth $41.6M. The stake represents 0.03% of the portfolio and ranks #439 among its holdings. This is a return to the name: Marshall Wace previously reported a position in XENE as recently as Q4 2025.

Marshall Wace first reported a position in XENE in Q4 2019 and has held it in 23 quarters since. The position peaked at $101M in Q3 2022. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Marshall Wace held 689,342 shares of Xenon Pharmaceuticals worth $41.6M as of Q2 2026.
  • Xenon Pharmaceuticals was a new Marshall Wace position in Q2 2026.
  • Xenon Pharmaceuticals made up 0.03% of Marshall Wace's portfolio in Q2 2026, its #439 holding.
  • Marshall Wace first reported a position in Xenon Pharmaceuticals in Q4 2019 and has held it in 23 quarters since.
  • Marshall Wace's Xenon Pharmaceuticals position peaked at $101M in Q3 2022.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.